000 01289 a2200373 4500
005 20250513150143.0
264 0 _c19980922
008 199809s 0 0 eng d
022 _a1042-8194
024 7 _a10.3109/10428199809068569
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aMyers, D E
245 0 0 _aLarge scale manufacturing of B43(anti-CD19)-genistein for clinical trials in leukemia and lymphoma.
_h[electronic resource]
260 _bLeukemia & lymphoma
_cApr 1998
300 _a329-38 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aAntibodies, Monoclonal
650 0 4 _aAntineoplastic Agents
_xtherapeutic use
650 0 4 _aGenistein
_xtherapeutic use
650 0 4 _aHumans
650 0 4 _aImmunoconjugates
_xchemistry
650 0 4 _aLeukemia
_xtherapy
650 0 4 _aLymphoma
_xtherapy
650 0 4 _aTumor Cells, Cultured
_xdrug effects
700 1 _aSicheneder, A
700 1 _aClementson, D
700 1 _aDvorak, N
700 1 _aVenkatachalam, T
700 1 _aSev, A R
700 1 _aChandan-Langlie, M
700 1 _aUckun, F M
773 0 _tLeukemia & lymphoma
_gvol. 29
_gno. 3-4
_gp. 329-38
856 4 0 _uhttps://doi.org/10.3109/10428199809068569
_zAvailable from publisher's website
999 _c9650657
_d9650657